https://www.selleckchem.com/pr....oducts/Mubritinib-TA
Adding stereotactic ablative radiotherapy (SABR) to standard treatment slowed 6-month disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay androgen deprivation therapy, according to findings from the phase II ORIOLE trial. Larger studies are needed to determine if SABR, alone or combined with immunotherapies, can prevent new metastases in some patients. ©2020 American Association for Cancer Research.Platelet-derived growth factor receptor-beta (PDGFRβ) is a receptor tyrosine kin
Like
Comment
Share
